CochLear (OTCMKTS:CHEOY) Sets New 12-Month Low – Should You Sell?

CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY) hit a new 52-week low during trading on Friday . The company traded as low as $70.31 and last traded at $70.58, with a volume of 880 shares traded. The stock had previously closed at $86.32.

CochLear News Summary

Here are the key news stories impacting CochLear this week:

• Positive Sentiment: Management is negotiating price increases which, if secured, could help recover margins and support future earnings. Cochlear’s 1H Profit Drops 21% After Price Rise Negotiations — Update
• Neutral Sentiment: Full Q2 earnings call transcript is available for investors who want management detail on timing of product launches, pricing talks and region‑level trends (useful for assessing recovery timelines). Cochlear Limited (CHEOY) Q2 2026 Earnings Call Transcript
• Negative Sentiment: 1H profit fell about 21% year‑over‑year and management gave muted near‑term guidance; that earnings miss and softer outlook are primary drivers of the stock decline. Cochlear shares slide on HY earnings drop, muted guidance
• Negative Sentiment: Delays to the NEXA/new implant launches are hitting profit timing and keeping revenue growth subdued; investors view product delays as a material execution risk. Cochlear’s Profit Impacted by Nexa Delays Cochlear shares hit three-year low on new implant delays
• Negative Sentiment: Currency headwinds: management and analysts warn AUD/USD moves are weighing on reported earnings; ANZ expects AUD ~US$0.73 which would amplify translation headwinds. ANZ says AUD heading for US $0.73 as Cochlear warns of currency impacts Cochlear CEO: AUD currency fluctuations weighing on earnings
• Negative Sentiment: Market reaction: multiple reports note the stock has plunged and hit multi‑year lows on the combined impact of weaker earnings, delays and FX concerns — expect continued volatility until product timelines and pricing outcomes are clearer. Cochlear crashes in latest earnings season carnage Cochlear Profit Drops, Shares Plunge
• Neutral Sentiment: Third‑party reviews and comparisons (analyst/coverage notes) are beginning to re‑rate the stock; investors should scan analyst notes for revised estimates. Reviewing CochLear (OTCMKTS:CHEOY) and CVS Health (NYSE:CVS)

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada upgraded CochLear from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, CochLear has a consensus rating of “Buy”.

CochLear Stock Down 18.6%

The company has a 50 day moving average of $89.52 and a 200 day moving average of $93.36.

About CochLear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.